TSVT - 2seventy bio Q1 2024 Earnings Preview
2024-05-07 13:19:48 ET
More on 2seventy bio
- 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
- 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript
- Bristol-Myers posts Q1 beat despite growth headwinds
- Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
- Seeking Alpha’s Quant Rating on 2seventy bio